Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: March 28, 2018
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.
Journal: PM & R : the journal of injury, function, and rehabilitation
Published: January 19, 2018
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Journal: BMC neurology
Published: September 04, 2016
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: August 05, 2016
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.
Journal: Pharmacology & therapeutics
Published: May 04, 2016
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.
Journal: JAMA
Published: March 16, 2016
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Journal: BMC neurology
Published: December 22, 2015
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Journal: CNS spectrums
Published: October 17, 2015
Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force.
Journal: The journal of prevention of Alzheimer's disease
Published: September 29, 2015
Last Updated: 09/26/2026